Ovarian Neoplasms Clinical Trials in Houston, Texas

6 studies are recruiting for ovarian neoplasms in Houston, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study of Sofe-M in Participants With Selected Advanced Solid Tumors

   The purpose of this study is to find out whether the study drug, Sofetabart Mipitecan (LY4170156), is safe, tolerable and effective in participants with advanced solid tumors. The study is conducted in three parts - phase Ia (dose-escalation, dose-optimization), phase Ib (dose-expansion), and phase…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The University of Texas - MD Anderson Cancer Center, Houston, Texas

   Locations

   24 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06400472 on ClinicalTrials.gov

2. A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

   This is a study of LY4337713 in participants with certain types of cancer that is advanced or has spread. Participants must have cancer with high levels of a protein called fibroblast activation protein (FAP). The purpose of this study is to evaluate safety, side effects, and efficacy of LY4337713.…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Baylor College of Medicine, Houston, Texas

   Locations

   30 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07213791 on ClinicalTrials.gov

3. Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

   Objective: To collect information on how often a solid tumor cancer might lose the Human Leukocyte Antigen (HLA) by next generation sequencing and perform apheresis to collect and store an eligible participant's own T cells for future use to make CAR T-Cell therapy for their disease treatment. Desi…

   Stage

   Not phased

   Ages

   18 and older

   Site

   MD Anderson Cancer Center, Houston, Texas

   Locations

   16 in total

   Run by

   A2 Biotherapeutics Inc.

   See if you can join NCT04981119 on ClinicalTrials.gov

4. A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

   The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab, docetaxel, or Pumitamig in participants with advanced solid tumors. This study is a first-in-human (FIH) study of BMS-986340 in participants with …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Houston Methodist Hospital, Houston, Texas

   Locations

   47 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT04895709 on ClinicalTrials.gov

5. A Study of DM002 in Patients With Advanced Solid Tumors

   The goal of study： The study has two parts: Part 1 Dose Escalation and Part 2 Dose Expansion. In Part 1, a few participants will receive the lowest dose of study drug. The study team will make sure it is safe and tolerated before enrolling new participants at a higher dose of study drug. There will…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The University of Texas, MD Anderson Cancer Center, Houston, Texas

   Locations

   7 in total

   Run by

   Xadcera Biopharmaceutical (Suzhou) Co., Ltd.

   See if you can join NCT06751329 on ClinicalTrials.gov

6. A Study of Sigvotatug Vedotin in Advanced Solid Tumors

   This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors. It will study sigvotatug vedotin to find out what its side effects are. A side effect is anything the drug …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Oncology Consultants, PA, Houston, Texas

   Locations

   158 in total

   Run by

   Seagen, a wholly owned subsidiary of Pfizer

   See if you can join NCT04389632 on ClinicalTrials.gov